No-Reflow in Patients With STEMI After Intracoronary Tirofiban After Opening of the Track

Kafrelsheikh University

Status: Enrolling

Conditions: No-Reflow; Tirofiban; Intracoronary; STEMI

Treatments: Drug: Intracoronary tirofiban; Drug: Saline 0.9%

Study type: Interventional

Funder types: Other

Identifiers

NCT06966674

KFSIRB200-587

Details and patient eligibility

About

This study aims to assess the no-reflow in patients with STEMI after intracoronary glycoprotein IIb/IIIa inhibitors after opening of track in thrombus.

Full description

ST-segment-elevation myocardial infarction (STEMI) is most commonly caused by rupture or erosion of an atherosclerotic plaque, resulting in acute occlusion of the coronary artery, and the preferred reperfusion strategy is primary percutaneous coronary intervention (PCI).

The no-reflow phenomenon is one of the most common causes of adverse cardiovascular events in patients STEMI.

In recent years, mechanical or pharmacological treatment strategies including adjunctive administration of glycoprotein IIb/IIIa inhibitors (GPI) have been proposed in patients with STEMI.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥ 18 years old.
• Both sexes.
• Patients with STEMI. ST-segment elevated myocardial infarction is defined as typical chest pain >30 minutes with ST-segment elevation of >1 mm in at least 2 consecutive leads on the electrocardiogram or new-onset left bundle brunch block.

Exclusion criteria

• Treatment with thrombolytic drugs in the previous 24 hours.
• Known malignancy.
• Thrombocytopenia.
• End-stage liver disease.
• Cardiogenic shock.
• Renal failure with glomerular filtration<30 ml/min.
• Contraindication for the use of tirofiban.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

60 participants in 2 patient groups, including a placebo group

Intracoronary tirofiban group

Experimental group

Description:

Patients will receive intracoronary tirofiban (Aggrastat®) (25 mg/kg)

Treatment:

Drug: Intracoronary tirofiban

Control group

Placebo Comparator group

Description:

Patients will receive intracoronary saline 0.9% solution as a control group.

Treatment:

Drug: Saline 0.9%